Open an account

SOPHiA GENETICS SA

SOPH · NASDAQ

$6.93+$0.44 (+6.78%)TodayMarket closed ·
Prev close $6.49

About SOPH

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. The company is headquartered in Rolle, Vaud and currently employs 415 full-time employees. The company went IPO on 2021-07-23. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The firm has offices in Switzerland, France, and the United States and operates worldwide.

Employees
415
Headquarters
Rolle, Vaud
Listed
Jul 23, 2021
Sector
Health Care
Industry
Health Care Technology
Website
sophiagenetics.com

SOPH key statistics

Market cap
589.94M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
621.41K
Volume
639.62K
Open price
$6.49
High today
$6.97
Low today
$6.39
52 Week high
$8.98
52 Week low
$3.75

SOPHiA GENETICS SA (SOPH) at a glance

As of Oct 20, 2026, SOPHiA GENETICS SA (SOPH) shares are priced at $6.93, giving the company a market cap of 589.94M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.39 and $6.97. The current price is 8.5% above the day's low and 0.6% below its high.

Volume so far is 639.62K shares, in line with the average of 621.41K shares a day.

Over the past year SOPHiA GENETICS SA has ranged from $3.75 to $8.98, and now sits 61% of the way up that range.

SOPHiA GENETICS SA met or beat analyst EPS estimates in 0 of the last 8 quarters. In Q2 FY26 it reported -$0.28 per share against an estimate of -$0.2142.

The average analyst price target is $9.94, 43.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $9.94
Low
$7.07
Now
$6.93
High
$14.70

SOPH earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 8 quarters.

  1. Q3 FY24: reported -$0.28 per share against an estimate of -$0.2346
  2. Q4 FY24: reported -$0.23 per share against an estimate of -$0.2285
  3. Q1 FY25: reported -$0.26 per share against an estimate of -$0.2525
  4. Q2 FY25: reported -$0.33 per share against an estimate of -$0.2346
  5. Q3 FY25: reported -$0.28 per share against an estimate of -$0.2474
  6. Q4 FY25: reported -$0.25 per share against an estimate of -$0.2423
  7. Q1 FY26: reported -$0.27 per share against an estimate of -$0.2372
  8. Q2 FY26: reported -$0.28 per share against an estimate of -$0.2142

SOPH news

  • Press releasePRNewswire

    SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026

  • Press releasePRNewswire

    SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

  • Press releasePRNewswire

    SOPHiA GENETICS Reports Second Quarter 2026 Results

  • Press releasePRNewswire

    SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

  • Press releasePRNewswire

    SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026

  • Press releasePRNewswire

    SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting

  • Press releasePRNewswire

    SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

  • Rishabh Mishra

    Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus (UPDATED)

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.